| Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation UM Zanger, M Schwab Pharmacology & therapeutics 138 (1), 103-141, 2013 | 4268 | 2013 |
| Metformin improves healthspan and lifespan in mice A Martin-Montalvo, EM Mercken, SJ Mitchell, HH Palacios, PL Mote, ... Nature communications 4 (1), 2192, 2013 | 1502 | 2013 |
| Reduced Paneth cell α-defensins in ileal Crohn's disease J Wehkamp, NH Salzman, E Porter, S Nuding, M Weichenthal, RE Petras, ... Proceedings of the National Academy of Sciences 102 (50), 18129-18134, 2005 | 1326 | 2005 |
| NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression J Wehkamp, J Harder, M Weichenthal, M Schwab, E Schäffeler, M Schlee, ... Gut 53 (11), 1658-1664, 2004 | 1144 | 2004 |
| Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects I Cascorbi, T Gerloff, A Johne, C Meisel, S Hoffmeyer, M Schwab, ... Clinical Pharmacology & Therapeutics 69 (3), 169-174, 2001 | 934 | 2001 |
| A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors M Filipits, M Rudas, R Jakesz, P Dubsky, F Fitzal, CF Singer, O Dietze, ... Clinical Cancer Research 17 (18), 6012-6020, 2011 | 801 | 2011 |
| Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation UM Zanger, M Turpeinen, K Klein, M Schwab Analytical and bioanalytical chemistry 392, 1093-1108, 2008 | 759 | 2008 |
| A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon K Fellermann, DE Stange, E Schaeffeler, H Schmalzl, J Wehkamp, ... The American Journal of Human Genetics 79 (3), 439-448, 2006 | 718 | 2006 |
| Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver T Lang, K Klein, J Fischer, AK Nüssler, P Neuhaus, U Hofmann, ... Pharmacogenetics and Genomics 11 (5), 399-415, 2001 | 712 | 2001 |
| Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen W Schroth, MP Goetz, U Hamann, PA Fasching, M Schmidt, S Winter, ... Jama 302 (13), 1429-1436, 2009 | 663 | 2009 |
| Sex is a major determinant of CYP3A4 expression in human liver R Wolbold, K Klein, O Burk, AK Nüssler, P Neuhaus, M Eichelbaum, ... Hepatology 38 (4), 978-988, 2003 | 619 | 2003 |
| Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes W Schroth, L Antoniadou, P Fritz, M Schwab, T Muerdter, UM Zanger, ... Journal of Clinical Oncology 25 (33), 5187-5193, 2007 | 600 | 2007 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ... Clinical Pharmacology & Therapeutics 103 (2), 210-216, 2018 | 596 | 2018 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update MV Relling, M Schwab, M Whirl‐Carrillo, G Suarez‐Kurtz, CH Pui, ... Clinical Pharmacology & Therapeutics 105 (5), 1095-1105, 2019 | 582 | 2019 |
| Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants E Schaeffeler, C Fischer, D Brockmeier, D Wernet, K Moerike, ... Pharmacogenetics and Genomics 14 (7), 407-417, 2004 | 524 | 2004 |
| High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) M Niemi, E Schaeffeler, T Lang, MF Fromm, M Neuvonen, C Kyrklund, ... Pharmacogenetics and Genomics 14 (7), 429-440, 2004 | 516 | 2004 |
| The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells M Hitzl, S Drescher, H van der Kuip, E Schäffeler, J Fischer, M Schwab, ... Pharmacogenetics and Genomics 11 (4), 293-298, 2001 | 515 | 2001 |
| Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group M Schwab, UM Zanger, C Marx, E Schaeffeler, K Klein, J Dippon, R Kerb, ... Journal of clinical oncology 26 (13), 2131-2138, 2008 | 486 | 2008 |
| NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity T Moriyama, R Nishii, V Perez-Andreu, W Yang, FA Klussmann, X Zhao, ... Nature genetics 48 (4), 367-373, 2016 | 483 | 2016 |
| Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study P Bogomolov, A Alexandrov, N Voronkova, M Macievich, K Kokina, ... Journal of hepatology 65 (3), 490-498, 2016 | 461 | 2016 |
